143 related articles for article (PubMed ID: 22432107)
1. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.
Rosenstock J; Shenouda SK; Bergenstal RM; Buse JB; Glass LC; Heilmann CR; Kwan AY; MacConell LA; Hoogwerf BJ
Diabetes Care; 2012 May; 35(5):955-8. PubMed ID: 22432107
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
Levin PA; Mersey JH; Zhou S; Bromberger LA
Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
[TBL] [Abstract][Full Text] [Related]
3. Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.
Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Faries D; Engelman W; Bruhn D; Bergenstal RM
Diabetes Obes Metab; 2012 Jul; 14(7):626-33. PubMed ID: 22321776
[TBL] [Abstract][Full Text] [Related]
4. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
Buse JB; Han J; Miller S; MacConell L; Pencek R; Wintle M
Curr Med Res Opin; 2014 Jul; 30(7):1209-18. PubMed ID: 24621255
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
6. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
Bunck MC; Diamant M; Cornér A; Eliasson B; Malloy JL; Shaginian RM; Deng W; Kendall DM; Taskinen MR; Smith U; Yki-Järvinen H; Heine RJ
Diabetes Care; 2009 May; 32(5):762-8. PubMed ID: 19196887
[TBL] [Abstract][Full Text] [Related]
7. Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine.
McCall AL; Cox DJ; Brodows R; Crean J; Johns D; Kovatchev B
Diabetes Technol Ther; 2009 Jun; 11(6):339-44. PubMed ID: 19459761
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.
Karagianni P; Polyzos SA; Kartali N; Zografou I; Sambanis C
Adv Med Sci; 2013; 58(1):38-43. PubMed ID: 23640946
[TBL] [Abstract][Full Text] [Related]
9. [Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes].
Kress S
Dtsch Med Wochenschr; 2010 May; 135(18):907-10. PubMed ID: 20425675
[TBL] [Abstract][Full Text] [Related]
10. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.
Pawaskar M; Li Q; Reynolds MW
Curr Med Res Opin; 2012 Jun; 28(6):991-7. PubMed ID: 22519390
[TBL] [Abstract][Full Text] [Related]
11. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.
Davies MJ; Donnelly R; Barnett AH; Jones S; Nicolay C; Kilcoyne A
Diabetes Obes Metab; 2009 Dec; 11(12):1153-62. PubMed ID: 19930005
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.
Secnik Boye K; Matza LS; Oglesby A; Malley K; Kim S; Hayes RP; Brodows R
Health Qual Life Outcomes; 2006 Oct; 4():80. PubMed ID: 17034640
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Lee LJ; Fonseca V
Endocr Pract; 2012; 18(5):700-11. PubMed ID: 22982784
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
15. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
[TBL] [Abstract][Full Text] [Related]
16. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.
Glass LC; Qu Y; Lenox S; Kim D; Gates JR; Brodows R; Trautmann M; Bergenstal RM
Curr Med Res Opin; 2008 Mar; 24(3):639-44. PubMed ID: 18218179
[TBL] [Abstract][Full Text] [Related]
17. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID.
Baser O; Wei W; Baser E; Xie L
J Med Econ; 2011; 14(6):673-80. PubMed ID: 21892858
[TBL] [Abstract][Full Text] [Related]
19. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas.
Davies M; Heller S; Sreenan S; Sapin H; Adetunji O; Tahbaz A; Vora J
Diabetes Care; 2013 May; 36(5):1368-76. PubMed ID: 23275363
[TBL] [Abstract][Full Text] [Related]
20. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.
Horton ES; Silberman C; Davis KL; Berria R
Diabetes Care; 2010 Aug; 33(8):1759-65. PubMed ID: 20460445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
